Genomic Health, Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 5,000 shares of Genomic Health stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $31.86, for a total value of $159,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, August 8th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $30.57, for a total value of $152,850.00.
  • On Tuesday, July 11th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $32.53, for a total value of $162,650.00.

Shares of Genomic Health, Inc. (GHDX) traded down 1.68% during mid-day trading on Thursday, hitting $30.96. The stock had a trading volume of 132,220 shares. The stock’s market capitalization is $1.07 billion. Genomic Health, Inc. has a 12-month low of $26.37 and a 12-month high of $33.97. The stock’s 50-day moving average price is $30.93 and its 200-day moving average price is $31.60.

Genomic Health (NASDAQ:GHDX) last released its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.02). The firm had revenue of $85.50 million for the quarter, compared to the consensus estimate of $86.08 million. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. Genomic Health’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.18) EPS. On average, equities analysts anticipate that Genomic Health, Inc. will post ($0.01) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Genomic Health, Inc. (GHDX) COO Sells 5,000 Shares of Stock” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/09/14/insider-selling-genomic-health-inc-ghdx-coo-sells-5000-shares-of-stock.html.

A number of brokerages recently issued reports on GHDX. Jefferies Group LLC restated a “hold” rating and issued a $33.00 target price on shares of Genomic Health in a report on Thursday. Canaccord Genuity decreased their target price on Genomic Health from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, August 15th. BidaskClub cut Genomic Health from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Piper Jaffray Companies restated a “hold” rating and issued a $31.00 target price on shares of Genomic Health in a report on Thursday, August 3rd. Finally, Zacks Investment Research cut Genomic Health from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. Genomic Health has a consensus rating of “Hold” and an average price target of $32.00.

A number of hedge funds have recently added to or reduced their stakes in the business. Wetherby Asset Management Inc. increased its holdings in Genomic Health by 3.7% during the 2nd quarter. Wetherby Asset Management Inc. now owns 8,912 shares of the medical research company’s stock worth $290,000 after purchasing an additional 317 shares in the last quarter. Dubuque Bank & Trust Co. increased its holdings in Genomic Health by 8.4% during the 2nd quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock worth $159,000 after purchasing an additional 379 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in Genomic Health by 5.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock worth $262,000 after purchasing an additional 441 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Genomic Health by 0.6% during the 1st quarter. Bank of New York Mellon Corp now owns 88,577 shares of the medical research company’s stock worth $2,789,000 after purchasing an additional 500 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Genomic Health by 3.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,857 shares of the medical research company’s stock worth $516,000 after purchasing an additional 520 shares in the last quarter. Hedge funds and other institutional investors own 88.91% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.